董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vickie L. Capps | 女 | Independent Director | 61 | 28.00万美元 | 未持股 | 2023-04-25 |
| Siddhartha C. Kadia | 男 | Independent Director | 53 | 26.00万美元 | 未持股 | 2023-04-25 |
| J. Christopher Barry | 男 | Chief Executive Officer and Director | 51 | 807.71万美元 | 未持股 | 2023-04-25 |
| John A. DeFord | 男 | Independent Director | 61 | 26.00万美元 | 未持股 | 2023-04-25 |
| Amy Belt Raimundo | 女 | Independent Director | 49 | 26.00万美元 | 未持股 | 2023-04-25 |
| R. Scott Huennekens | 男 | Independent Director | 59 | 26.00万美元 | 未持股 | 2023-04-25 |
| Robert F. Friel | 男 | Independent Director | 67 | 26.00万美元 | 未持股 | 2023-04-25 |
| Leslie V. Norwalk | 女 | Independent Director | 57 | 27.00万美元 | 未持股 | 2023-04-25 |
| Daniel J. Wolterman | 男 | Chairman of the Board,Independent Director | 66 | 40.50万美元 | 未持股 | 2023-04-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Christopher Barry | 男 | Chief Executive Officer and Director | 51 | 807.71万美元 | 未持股 | 2023-04-25 |
| Nathaniel B. Sisitsky | 男 | Senior Vice President, General Counsel and Corporate Secretary | 49 | 154.29万美元 | 未持股 | 2023-04-25 |
| Dale Wolf | 男 | Senior Vice President, Global Operations | 43 | 148.26万美元 | 未持股 | 2023-04-25 |
| Michael Farrington | 男 | Senior Vice President, People and Culture | 39 | 102.66万美元 | 未持股 | 2023-04-25 |
| Matthew K. Harbaugh | 男 | Executive Vice President, Chief Financial Officer | 52 | 297.05万美元 | 未持股 | 2023-04-25 |
董事简历
中英对照 | 中文 | 英文- Vickie L. Capps
-
Vickie L. Capps，曾担任多家上市和私营公司的首席财务官。从2002年到2013年，Capps女士担任DJO Global, Inc.（全球领先的肌肉骨骼健康、血管健康和疼痛管理医疗设备解决方案提供商）的执行副总裁、首席财务官和财务主管，并于2009年和2010年被the San Diego Business Journal评为年度首席财务官。在职业生涯早期，她曾担任Ernst & Young LLP的高级审计和会计专业人员。
Vickie L. Capps,previously served as chief financial officer of several public and private companies. From 2002 to 2013, Ms. Capps served as the Executive Vice President, Chief Financial Officer and Treasurer at DJO Global, Inc. a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, where she was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. Earlier in her career, she served as a senior audit and accounting professional at Ernst & Young LLP. - Vickie L. Capps，曾担任多家上市和私营公司的首席财务官。从2002年到2013年，Capps女士担任DJO Global, Inc.（全球领先的肌肉骨骼健康、血管健康和疼痛管理医疗设备解决方案提供商）的执行副总裁、首席财务官和财务主管，并于2009年和2010年被the San Diego Business Journal评为年度首席财务官。在职业生涯早期，她曾担任Ernst & Young LLP的高级审计和会计专业人员。
- Vickie L. Capps,previously served as chief financial officer of several public and private companies. From 2002 to 2013, Ms. Capps served as the Executive Vice President, Chief Financial Officer and Treasurer at DJO Global, Inc. a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, where she was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. Earlier in her career, she served as a senior audit and accounting professional at Ernst & Young LLP.
- Siddhartha C. Kadia
-
Siddhartha C. Kadia ，他于2014年12月被任命为董事。2014年4月以来，他一直担任Evans Analytical Group（高精度的实验室检测、评估和分析服务的领先全球供应商）的总裁兼首席执行官、董事。加入Evans Analytical Group公司之前，他曾任职Life Technologies Corporation（全球生物科技公）（从2008年7月到2014年2月），担任多种管理职务，最近担任生命科学部门总裁（从2013年4月到2014年2月）、Life Technologies Greater China的总裁（从2011年4月到2013年4月）、Life Technologies Japan公司的总裁（从2009年7月到2011年4月）、首席营销官（从2008年7月到2009年6月）。从2005年7月到2008年7月，他曾担任Invitrogen Corporation（一个生物科技公司，于2008年与Applied Biosystems公司合并创立Life Technologies公司）的多种职务，包括最近担任负责全球市场营销和电子商务的副总裁（从2007年7月到2008年7月）。加入Invitrogen Corporation之前，他曾担任McKinsey & Company（全球领先的咨询公司）的管理顾问，在那里他曾涉及美国和欧洲生活和健康科学公司的多种战略和运营问题。他曾任职于Volcano Corporation（医疗技术公司）的董事会（从2013年3月到2015年2月公司被Royal Philips公司收购）。
Siddhartha C. Kadia was appointed to the Board in December 2014. Since April 2014 Dr. Kadia has served as President and Chief Executive Officer, and as a director, of EAG, Inc. Evans Analytical Group, a leading global provider of high-precision laboratory testing, evaluation and analytical services. Prior to joining EAG, Inc., Dr. Kadia was employed by Life Technologies Corporation, a global biotechnology company, from July 2008 to February 2014 holding a number of management positions, most recently President of the Life Sciences Division from April 2013 to February 2014 President of Life Technologies Greater China from April 2011 to April 2013 President of Life Technologies Japan Ltd. from July 2009 to April 2011 and Chief Marketing Officer from July 2008 to June 2009. From July 2005 to July 2008 Dr. Kadia served in numerous roles at Invitrogen Corporation, a biotechnology company that was merged with Applied Biosystems, Inc. in 2008 to form Life Technologies, including most recently as Vice President of Global Marketing and eBusiness from July 2007 to July 2008. Before joining Invitrogen Corporation, Dr. Kadia was a management consultant at McKinsey & Company, a leading global consulting firm, where he worked with life and health sciences companies in the U.S. and Europe on a wide range of strategic and operational matters. Dr. Kadia served on the board of directors of Volcano Corporation, a medical technology company, from March 2013 until the company was acquired by Royal Philips N.V. in February 2015. - Siddhartha C. Kadia ，他于2014年12月被任命为董事。2014年4月以来，他一直担任Evans Analytical Group（高精度的实验室检测、评估和分析服务的领先全球供应商）的总裁兼首席执行官、董事。加入Evans Analytical Group公司之前，他曾任职Life Technologies Corporation（全球生物科技公）（从2008年7月到2014年2月），担任多种管理职务，最近担任生命科学部门总裁（从2013年4月到2014年2月）、Life Technologies Greater China的总裁（从2011年4月到2013年4月）、Life Technologies Japan公司的总裁（从2009年7月到2011年4月）、首席营销官（从2008年7月到2009年6月）。从2005年7月到2008年7月，他曾担任Invitrogen Corporation（一个生物科技公司，于2008年与Applied Biosystems公司合并创立Life Technologies公司）的多种职务，包括最近担任负责全球市场营销和电子商务的副总裁（从2007年7月到2008年7月）。加入Invitrogen Corporation之前，他曾担任McKinsey & Company（全球领先的咨询公司）的管理顾问，在那里他曾涉及美国和欧洲生活和健康科学公司的多种战略和运营问题。他曾任职于Volcano Corporation（医疗技术公司）的董事会（从2013年3月到2015年2月公司被Royal Philips公司收购）。
- Siddhartha C. Kadia was appointed to the Board in December 2014. Since April 2014 Dr. Kadia has served as President and Chief Executive Officer, and as a director, of EAG, Inc. Evans Analytical Group, a leading global provider of high-precision laboratory testing, evaluation and analytical services. Prior to joining EAG, Inc., Dr. Kadia was employed by Life Technologies Corporation, a global biotechnology company, from July 2008 to February 2014 holding a number of management positions, most recently President of the Life Sciences Division from April 2013 to February 2014 President of Life Technologies Greater China from April 2011 to April 2013 President of Life Technologies Japan Ltd. from July 2009 to April 2011 and Chief Marketing Officer from July 2008 to June 2009. From July 2005 to July 2008 Dr. Kadia served in numerous roles at Invitrogen Corporation, a biotechnology company that was merged with Applied Biosystems, Inc. in 2008 to form Life Technologies, including most recently as Vice President of Global Marketing and eBusiness from July 2007 to July 2008. Before joining Invitrogen Corporation, Dr. Kadia was a management consultant at McKinsey & Company, a leading global consulting firm, where he worked with life and health sciences companies in the U.S. and Europe on a wide range of strategic and operational matters. Dr. Kadia served on the board of directors of Volcano Corporation, a medical technology company, from March 2013 until the company was acquired by Royal Philips N.V. in February 2015.
- J. Christopher Barry
-
J.Christopher Barry自2018年11月起担任我们的首席执行官兼董事。在加入NuVasive之前，Barry先生于2015年1月至2018年10月担任全球医疗技术公司美敦力（Medtronic plc）的高级副总裁兼手术创新总裁。Barry先生在2015年1月收购全球梦百合技术和医疗用品供应商Covidien plc后加入美敦力。Barry从2013年10月到2015年1月在Covidien任职15年，担任多个销售和领导职位，最近担任Advanced Surgical Technologies总裁。
J. Christopher Barry,has served as Nuvasive, Inc. Chief Executive Officer and a Director since November 2018.Prior to joining NuVasive, Mr. Barry served as Senior Vice President and President of Surgical Innovations for Medtronic plc, a global medical technology company, from January 2015 to October 2018. Mr. Barry joined Medtronic following its January 2015 acquisition of Covidien plc, a global healthcare technology and medical supplies provider. Mr. Barry previously spent 15 years with Covidien in various sales and leadership roles, most recently as President, Advanced Surgical Technologies, from October 2013 to January 2015. - J.Christopher Barry自2018年11月起担任我们的首席执行官兼董事。在加入NuVasive之前，Barry先生于2015年1月至2018年10月担任全球医疗技术公司美敦力（Medtronic plc）的高级副总裁兼手术创新总裁。Barry先生在2015年1月收购全球梦百合技术和医疗用品供应商Covidien plc后加入美敦力。Barry从2013年10月到2015年1月在Covidien任职15年，担任多个销售和领导职位，最近担任Advanced Surgical Technologies总裁。
- J. Christopher Barry,has served as Nuvasive, Inc. Chief Executive Officer and a Director since November 2018.Prior to joining NuVasive, Mr. Barry served as Senior Vice President and President of Surgical Innovations for Medtronic plc, a global medical technology company, from January 2015 to October 2018. Mr. Barry joined Medtronic following its January 2015 acquisition of Covidien plc, a global healthcare technology and medical supplies provider. Mr. Barry previously spent 15 years with Covidien in various sales and leadership roles, most recently as President, Advanced Surgical Technologies, from October 2013 to January 2015.
- John A. DeFord
-
John A. DeFord于2021年从Becton、Dickinson和NYSE：BDX公司退休，Becton、Dickinson是一家全球领先的医疗技术公司，生产和销售医疗设备、仪器系统和试剂。自2017年BDX收购C.R.Bard，Inc.以来，他一直担任执行副总裁兼首席技术官，直至2021。此前，DeFord博士是C.R.Bard，股份有限公司的科学、技术和临床事务高级副总裁。在收购时，C.R。Bard，股份有限公司是创新、血管、泌尿、肿瘤和外科专业产品领域的生命增强医疗技术。他之前的工作经验包括担任风险投资基金Early Stage Partners的常务董事，以及私人医疗器械制造商库克集团（Cook Group Incorporated）的总裁兼首席执行官。DeFord博士是NuVasive，Inc.（纳斯达克代码：NUVA）的董事，一家医疗器械公司，专注于微创手术和世界级外科医生教育的医疗器械和程序，他是提名、公司治理和合规委员会的成员。
John A. DeFord,currently chairman, chief executive officer and president of Samothrace Medical Innovations, Inc., a privately held medical technology company, which he co-founded in March 2022. Previously, Dr. DeFord served as executive vice president and chief technology officer of Becton, Dickinson and Company (NYSE: BDX) (medical technology and manufacturing) from 2017 until 2021. Prior to that, he was senior vice president of Science, Technology and Clinical Affairs for C.R. Bard, Inc. (medical technology manufacturing), which was acquired by BDX in 2017, managing director of Early Stage Partners, a venture capital fund, and president and chief executive officer of Cook Incorporated, a privately held medical device manufacturer.Dr. DeFord holds 14 U.S. patents, is the author of numerous peer-reviewed scientific papers, and has a Ph.D in Electrical Engineering. - John A. DeFord于2021年从Becton、Dickinson和NYSE：BDX公司退休，Becton、Dickinson是一家全球领先的医疗技术公司，生产和销售医疗设备、仪器系统和试剂。自2017年BDX收购C.R.Bard，Inc.以来，他一直担任执行副总裁兼首席技术官，直至2021。此前，DeFord博士是C.R.Bard，股份有限公司的科学、技术和临床事务高级副总裁。在收购时，C.R。Bard，股份有限公司是创新、血管、泌尿、肿瘤和外科专业产品领域的生命增强医疗技术。他之前的工作经验包括担任风险投资基金Early Stage Partners的常务董事，以及私人医疗器械制造商库克集团（Cook Group Incorporated）的总裁兼首席执行官。DeFord博士是NuVasive，Inc.（纳斯达克代码：NUVA）的董事，一家医疗器械公司，专注于微创手术和世界级外科医生教育的医疗器械和程序，他是提名、公司治理和合规委员会的成员。
- John A. DeFord,currently chairman, chief executive officer and president of Samothrace Medical Innovations, Inc., a privately held medical technology company, which he co-founded in March 2022. Previously, Dr. DeFord served as executive vice president and chief technology officer of Becton, Dickinson and Company (NYSE: BDX) (medical technology and manufacturing) from 2017 until 2021. Prior to that, he was senior vice president of Science, Technology and Clinical Affairs for C.R. Bard, Inc. (medical technology manufacturing), which was acquired by BDX in 2017, managing director of Early Stage Partners, a venture capital fund, and president and chief executive officer of Cook Incorporated, a privately held medical device manufacturer.Dr. DeFord holds 14 U.S. patents, is the author of numerous peer-reviewed scientific papers, and has a Ph.D in Electrical Engineering.
- Amy Belt Raimundo
-
Amy Belt Raimundo目前是Kaiser Permanente Ventures的董事总经理，Kaiser Permanente是Kaiser Permanente的风险投资部门，专注于健康信息技术、数字健康、医疗保健服务、医疗设备和诊断以及精准医疗领域的投资。在加入Kaiser Permanente Ventures之前，Raimundo女士于2015年3月至2016年10月担任健康分析数据公司Evidation Health的首席商务官。在加入Evidation Health之前，Raimundo女士于2010年9月至2015年2月担任Covidien Ventures副总裁，并于2006年11月至2010年9月担任Advanced Technology Ventures副总裁。她还曾在Guidant公司担任运营职务，并担任APM/CSC Healthcare的管理顾问，在那里她优化了主要医院系统的临床工作流程和指南。Raimundo女士是Kauffman Venture Fellow以及Medtech Women的创始人和总裁，Medtech Women是一个致力于突出医疗技术行业女性领导者的非营利组织。
Amy Belt Raimundo,is currently a Managing Director of Kaiser Permanente Ventures, a venture capital arm of Kaiser Permanente that focuses on investments in health information technology, digital health, healthcare services, medical devices and diagnostics and precision medicine.Prior to joining Kaiser Permanente Ventures, Ms. Raimundo was the Chief Business Officer of Evidation Health, a health analytics data company, from March 2015 through October 2016. Prior to joining Evidation Health, Ms. Raimundo served as Vice President of Covidien Ventures from September 2010 through February 2015, and as Vice President of Advanced Technology Ventures from November 2006 through September 2010. She also previously held operating roles at Guidant Corporation and served as a management consultant for APM/CSC Healthcare where she optimized clinical workflow and guidelines for major hospital systems. Ms. Raimundo is a Kauffman Venture Fellow as well as founder and President of Medtech Women, a nonprofit organization dedicated to highlighting women leaders in the medical technology industry. - Amy Belt Raimundo目前是Kaiser Permanente Ventures的董事总经理，Kaiser Permanente是Kaiser Permanente的风险投资部门，专注于健康信息技术、数字健康、医疗保健服务、医疗设备和诊断以及精准医疗领域的投资。在加入Kaiser Permanente Ventures之前，Raimundo女士于2015年3月至2016年10月担任健康分析数据公司Evidation Health的首席商务官。在加入Evidation Health之前，Raimundo女士于2010年9月至2015年2月担任Covidien Ventures副总裁，并于2006年11月至2010年9月担任Advanced Technology Ventures副总裁。她还曾在Guidant公司担任运营职务，并担任APM/CSC Healthcare的管理顾问，在那里她优化了主要医院系统的临床工作流程和指南。Raimundo女士是Kauffman Venture Fellow以及Medtech Women的创始人和总裁，Medtech Women是一个致力于突出医疗技术行业女性领导者的非营利组织。
- Amy Belt Raimundo,is currently a Managing Director of Kaiser Permanente Ventures, a venture capital arm of Kaiser Permanente that focuses on investments in health information technology, digital health, healthcare services, medical devices and diagnostics and precision medicine.Prior to joining Kaiser Permanente Ventures, Ms. Raimundo was the Chief Business Officer of Evidation Health, a health analytics data company, from March 2015 through October 2016. Prior to joining Evidation Health, Ms. Raimundo served as Vice President of Covidien Ventures from September 2010 through February 2015, and as Vice President of Advanced Technology Ventures from November 2006 through September 2010. She also previously held operating roles at Guidant Corporation and served as a management consultant for APM/CSC Healthcare where she optimized clinical workflow and guidelines for major hospital systems. Ms. Raimundo is a Kauffman Venture Fellow as well as founder and President of Medtech Women, a nonprofit organization dedicated to highlighting women leaders in the medical technology industry.
- R. Scott Huennekens
-
R. Scott Huennekens，2002年4月起，担任本公司的总裁、首席执行官、董事。2000年1月至2002年3月，他是医学影像公司Digirad Corporation的总裁、首席执行官。他目前是 Medical Device Manufacturers Association MDMA的董事，这是一个全国性的行业协会。
R. Scott Huennekens,most recently served as the interim President and CEO of Hyperfine, Inc., a medical technology company focused on creating access to life-saving diagnostics and actionable data at the point of care, from June 2022 to October 2022.From August 2015 to December 2018, Mr. Huennekens served as the President, Chief Executive Officer and Chairman of the Board of Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop an advanced digital surgery platform. Prior to joining Verb Surgical, Mr. Huennekens was the President, Chief Executive Officer and a member of the Board of Directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider, and previously served as its Chief Financial Officer. - R. Scott Huennekens，2002年4月起，担任本公司的总裁、首席执行官、董事。2000年1月至2002年3月，他是医学影像公司Digirad Corporation的总裁、首席执行官。他目前是 Medical Device Manufacturers Association MDMA的董事，这是一个全国性的行业协会。
- R. Scott Huennekens,most recently served as the interim President and CEO of Hyperfine, Inc., a medical technology company focused on creating access to life-saving diagnostics and actionable data at the point of care, from June 2022 to October 2022.From August 2015 to December 2018, Mr. Huennekens served as the President, Chief Executive Officer and Chairman of the Board of Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop an advanced digital surgery platform. Prior to joining Verb Surgical, Mr. Huennekens was the President, Chief Executive Officer and a member of the Board of Directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider, and previously served as its Chief Financial Officer.
- Robert F. Friel
-
Robert F. Friel目前担任Perkin Elmer公司的主席、行政总裁兼总裁。在2008年2月被任命为总裁兼首席执行官和2009年4月被任命为董事长之前，他自2007年8月起担任总裁兼首席运营官，自2006年1月起担任副董事长兼总裁，从2004年10月至2006年1月除了监督财务外还负责业务发展和信息技术。1999年2月，他作为公司执行副总裁兼财务总监加入Perkin Elmer。在加入公司之前，他在AlliedSignal公司（现在是Honeywell International）担任多个高级管理职位。他从费尔利迪金森大学获得经济学学士学位，从拉斐特学院获得税务学硕士学位。他目前是CareFusion公司和Xylem公司的董事，并曾担任Fairchild半导体公司和千年制药公司的董事。他还曾担任国家局优生优育基金会的信托董事。主要职位：Perkin Elmer的主席、行政总裁兼总裁、2006年起Perkin Elmer的董事以及财务委员会委员。
Robert F. Friel,Perkin Elmer (1999-2019), serving as Chief Operating Officer, Chief Financial Officer and in other senior leadership roles;Mr. Friel holds a Master of Science degree in taxation from Fairleigh Dickinson University and a Bachelor of Arts degree in economics from Lafayette College. In addition to the public board membership listed above, Mr. Friel is a director of New York Life Insurance Company, one of the largest life insurers in the world. - Robert F. Friel目前担任Perkin Elmer公司的主席、行政总裁兼总裁。在2008年2月被任命为总裁兼首席执行官和2009年4月被任命为董事长之前，他自2007年8月起担任总裁兼首席运营官，自2006年1月起担任副董事长兼总裁，从2004年10月至2006年1月除了监督财务外还负责业务发展和信息技术。1999年2月，他作为公司执行副总裁兼财务总监加入Perkin Elmer。在加入公司之前，他在AlliedSignal公司（现在是Honeywell International）担任多个高级管理职位。他从费尔利迪金森大学获得经济学学士学位，从拉斐特学院获得税务学硕士学位。他目前是CareFusion公司和Xylem公司的董事，并曾担任Fairchild半导体公司和千年制药公司的董事。他还曾担任国家局优生优育基金会的信托董事。主要职位：Perkin Elmer的主席、行政总裁兼总裁、2006年起Perkin Elmer的董事以及财务委员会委员。
- Robert F. Friel,Perkin Elmer (1999-2019), serving as Chief Operating Officer, Chief Financial Officer and in other senior leadership roles;Mr. Friel holds a Master of Science degree in taxation from Fairleigh Dickinson University and a Bachelor of Arts degree in economics from Lafayette College. In addition to the public board membership listed above, Mr. Friel is a director of New York Life Insurance Company, one of the largest life insurers in the world.
- Leslie V. Norwalk
-
Leslie V. Norwalk，2012年5月起担任董事长。2013年2月起，她还担任遵约委员会成员。她现在是Epstein Becker Green、EBG Advisors和National Health Advisors战略顾问。2008年起，她一直担任私人股权公司Warburg Pincus、Ferrer Freeman & Company和Enhanced Equity Fund顾问。2015年5月起，她担任Endologix, Inc.董事长；2014年5月起担任NuVasive, Inc.董事长；2013年起担任Adobe Healthcare和 STARUS Medical Group董事长；2012年起担任LWU Medical Faculty Associates董事长；2011年起担任Volcano Corporation董事长；2010年起担任Ika Systems Corporation董事长。她曾在George H.W.Bush政府任职，自2006年到2007年担任CMS代理管理员。她获得了Wellesley College文学士学位和George Mason University School of Law 法学博士。
Leslie V. Norwalk,Since September 2007, Ms. Norwalk has served as Strategic Counsel to Epstein Becker & Green, P.C. From 2001 to 2007, Ms. Norwalk served the Bush Administration in the Centers for Medicare & Medicaid Services (CMS). From 2006 to 2007, she was the Acting Administrator, where she managed the operations of federal health care programs, including Medicare and Medicaid. For the four years prior to that position, she was the agency's Deputy Administrator. Prior to serving the Bush Administration, Ms. Norwalk practiced law with Epstein Becker & Green, P.C. where she advised clients on a variety of healthcare policy matters. She also served the first Bush administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative. Ms. Norwalk is currently a director on the public company boards of NuVasive Inc., a medical device company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Arvinas Inc., a clinical-stage biopharmaceutical company. She also serves as an Advisor to several private equity funds. She received a bachelor's degree from Wellesley College and a juris doctor degree from George Mason University School of Law. - Leslie V. Norwalk，2012年5月起担任董事长。2013年2月起，她还担任遵约委员会成员。她现在是Epstein Becker Green、EBG Advisors和National Health Advisors战略顾问。2008年起，她一直担任私人股权公司Warburg Pincus、Ferrer Freeman & Company和Enhanced Equity Fund顾问。2015年5月起，她担任Endologix, Inc.董事长；2014年5月起担任NuVasive, Inc.董事长；2013年起担任Adobe Healthcare和 STARUS Medical Group董事长；2012年起担任LWU Medical Faculty Associates董事长；2011年起担任Volcano Corporation董事长；2010年起担任Ika Systems Corporation董事长。她曾在George H.W.Bush政府任职，自2006年到2007年担任CMS代理管理员。她获得了Wellesley College文学士学位和George Mason University School of Law 法学博士。
- Leslie V. Norwalk,Since September 2007, Ms. Norwalk has served as Strategic Counsel to Epstein Becker & Green, P.C. From 2001 to 2007, Ms. Norwalk served the Bush Administration in the Centers for Medicare & Medicaid Services (CMS). From 2006 to 2007, she was the Acting Administrator, where she managed the operations of federal health care programs, including Medicare and Medicaid. For the four years prior to that position, she was the agency's Deputy Administrator. Prior to serving the Bush Administration, Ms. Norwalk practiced law with Epstein Becker & Green, P.C. where she advised clients on a variety of healthcare policy matters. She also served the first Bush administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative. Ms. Norwalk is currently a director on the public company boards of NuVasive Inc., a medical device company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Arvinas Inc., a clinical-stage biopharmaceutical company. She also serves as an Advisor to several private equity funds. She received a bachelor's degree from Wellesley College and a juris doctor degree from George Mason University School of Law.
- Daniel J. Wolterman
-
Daniel J. Wolterman，2013年9月起担任本公司董事。他于1999年加入Memorial Hermann Health System；2002年，当选为董事，并被任命为总裁、首席执行官。加入Memorial Hermann之前，他是Sisters of Charity of the Incarnate Word Health Care System的高级副总裁。他有着30多年的医疗保健行业的经验，以及长久的社区服务经历。他曾担任许多机构的主席，包括：Greater Houston Partnership、Texas Hospital Association（董事长）、Voluntary Hospitals of America - Texas （董事长）、2011 National Senior Olympic Games。他目前是休斯敦地区American Heart Association的董事，也是该机构的前任主席。他还是Joint Commission's Center for Transforming Healthcare Leadership顾问委员会的成员，并继续担任Greater Houston Partnership, Texas Hospital Association, and Voluntary Hospitals of America Boards of Directors的成员。除了担任Memorial Hermann的总裁、首席执行官，以及市级、州级、全国性的许多委员会的成员，他还是The University of Texas School of Public Health的客座教授，也是University of Houston - Clear Lake Healthcare Administration Program 顾问委员会的成员。他是American College of Healthcare Executives的资深会员。
Daniel J. Wolterman,is currently Chief Executive Officer of Wolterman Consulting LLC, a provider of strategic and operational consulting services to healthcare providers and other entities.From January 2018 to May 2019, Mr. Wolterman served as Chief Executive Officer of ColubrisMX, Inc. and X-Cath, Inc., both privately held medical device companies. Mr. Wolterman previously served as President and Chief Executive Officer of Memorial Hermann Health System, the largest not-for-profit health system in Southeast Texas, from 2002 until his retirement from Memorial Hermann in May 2016. He has more than 40 years of experience in the healthcare industry and a long history of community involvement. - Daniel J. Wolterman，2013年9月起担任本公司董事。他于1999年加入Memorial Hermann Health System；2002年，当选为董事，并被任命为总裁、首席执行官。加入Memorial Hermann之前，他是Sisters of Charity of the Incarnate Word Health Care System的高级副总裁。他有着30多年的医疗保健行业的经验，以及长久的社区服务经历。他曾担任许多机构的主席，包括：Greater Houston Partnership、Texas Hospital Association（董事长）、Voluntary Hospitals of America - Texas （董事长）、2011 National Senior Olympic Games。他目前是休斯敦地区American Heart Association的董事，也是该机构的前任主席。他还是Joint Commission's Center for Transforming Healthcare Leadership顾问委员会的成员，并继续担任Greater Houston Partnership, Texas Hospital Association, and Voluntary Hospitals of America Boards of Directors的成员。除了担任Memorial Hermann的总裁、首席执行官，以及市级、州级、全国性的许多委员会的成员，他还是The University of Texas School of Public Health的客座教授，也是University of Houston - Clear Lake Healthcare Administration Program 顾问委员会的成员。他是American College of Healthcare Executives的资深会员。
- Daniel J. Wolterman,is currently Chief Executive Officer of Wolterman Consulting LLC, a provider of strategic and operational consulting services to healthcare providers and other entities.From January 2018 to May 2019, Mr. Wolterman served as Chief Executive Officer of ColubrisMX, Inc. and X-Cath, Inc., both privately held medical device companies. Mr. Wolterman previously served as President and Chief Executive Officer of Memorial Hermann Health System, the largest not-for-profit health system in Southeast Texas, from 2002 until his retirement from Memorial Hermann in May 2016. He has more than 40 years of experience in the healthcare industry and a long history of community involvement.
高管简历
中英对照 | 中文 | 英文- J. Christopher Barry
J.Christopher Barry自2018年11月起担任我们的首席执行官兼董事。在加入NuVasive之前，Barry先生于2015年1月至2018年10月担任全球医疗技术公司美敦力（Medtronic plc）的高级副总裁兼手术创新总裁。Barry先生在2015年1月收购全球梦百合技术和医疗用品供应商Covidien plc后加入美敦力。Barry从2013年10月到2015年1月在Covidien任职15年，担任多个销售和领导职位，最近担任Advanced Surgical Technologies总裁。
J. Christopher Barry,has served as Nuvasive, Inc. Chief Executive Officer and a Director since November 2018.Prior to joining NuVasive, Mr. Barry served as Senior Vice President and President of Surgical Innovations for Medtronic plc, a global medical technology company, from January 2015 to October 2018. Mr. Barry joined Medtronic following its January 2015 acquisition of Covidien plc, a global healthcare technology and medical supplies provider. Mr. Barry previously spent 15 years with Covidien in various sales and leadership roles, most recently as President, Advanced Surgical Technologies, from October 2013 to January 2015.- J.Christopher Barry自2018年11月起担任我们的首席执行官兼董事。在加入NuVasive之前，Barry先生于2015年1月至2018年10月担任全球医疗技术公司美敦力（Medtronic plc）的高级副总裁兼手术创新总裁。Barry先生在2015年1月收购全球梦百合技术和医疗用品供应商Covidien plc后加入美敦力。Barry从2013年10月到2015年1月在Covidien任职15年，担任多个销售和领导职位，最近担任Advanced Surgical Technologies总裁。
- J. Christopher Barry,has served as Nuvasive, Inc. Chief Executive Officer and a Director since November 2018.Prior to joining NuVasive, Mr. Barry served as Senior Vice President and President of Surgical Innovations for Medtronic plc, a global medical technology company, from January 2015 to October 2018. Mr. Barry joined Medtronic following its January 2015 acquisition of Covidien plc, a global healthcare technology and medical supplies provider. Mr. Barry previously spent 15 years with Covidien in various sales and leadership roles, most recently as President, Advanced Surgical Technologies, from October 2013 to January 2015.
- Nathaniel B. Sisitsky
Nathaniel B.Sisitsky，Esq.自2018年6月起担任我们的高级副总裁，总法律顾问兼公司秘书，负责领导NuVasive的法律团队。在这个职位上，他还监管我们的房地产和设施功能以及the Nuvasive Spine Foundation。Sisitsky先生曾于2015年7月至2018年6月担任公司事务Vice President兼副总法律顾问。在加入NuVasive之前，Sisitsky先生于2009年4月至2015年4月担任康尔福盛医疗集团Vice President兼副总法律顾问。从2004年8月到2009年4月，Sisitsky先生担任American Tower Corporation法律公司融资部的Vice President。在加入American Tower之前，Sisitsky先生是位于马萨诸塞州波士顿的Wilmer Cutler Pickering Hale and Dorr Wilmerhale企业部门的初级合伙人。
Nathaniel B. Sisitsky,has served as Nuvasive, Inc. Senior Vice President, General Counsel and Corporate Secretary since June 2018 and is responsible for leadership of NuVasive's legal team. In this role, Mr. Sisitsky also oversees the Company's Global Risk & Integrity team, as well as the NuVasive Spine Foundation.Mr. Sisitsky previously served as Nuvasive, Inc. Vice President and Associate General Counsel, Corporate Affairs from July 2015 to June 2018. Prior to joining NuVasive, Mr. Sisitsky was Vice President and Associate General Counsel at CareFusion Corporation, a global medical technology company focused on medication management and patient safety solutions, from April 2009 until April 2015. From August 2004 until April 2009, Mr. Sisitsky served as Vice President, Legal – Corporate Finance at American Tower Corporation, a global owner and operator of wireless communication sites. Prior to joining American Tower, Mr. Sisitsky was a Junior Partner in the Corporate Department of Wilmer Cutler Pickering Hale and Dorr (WilmerHale), based in Boston, MA.- Nathaniel B.Sisitsky，Esq.自2018年6月起担任我们的高级副总裁，总法律顾问兼公司秘书，负责领导NuVasive的法律团队。在这个职位上，他还监管我们的房地产和设施功能以及the Nuvasive Spine Foundation。Sisitsky先生曾于2015年7月至2018年6月担任公司事务Vice President兼副总法律顾问。在加入NuVasive之前，Sisitsky先生于2009年4月至2015年4月担任康尔福盛医疗集团Vice President兼副总法律顾问。从2004年8月到2009年4月，Sisitsky先生担任American Tower Corporation法律公司融资部的Vice President。在加入American Tower之前，Sisitsky先生是位于马萨诸塞州波士顿的Wilmer Cutler Pickering Hale and Dorr Wilmerhale企业部门的初级合伙人。
- Nathaniel B. Sisitsky,has served as Nuvasive, Inc. Senior Vice President, General Counsel and Corporate Secretary since June 2018 and is responsible for leadership of NuVasive's legal team. In this role, Mr. Sisitsky also oversees the Company's Global Risk & Integrity team, as well as the NuVasive Spine Foundation.Mr. Sisitsky previously served as Nuvasive, Inc. Vice President and Associate General Counsel, Corporate Affairs from July 2015 to June 2018. Prior to joining NuVasive, Mr. Sisitsky was Vice President and Associate General Counsel at CareFusion Corporation, a global medical technology company focused on medication management and patient safety solutions, from April 2009 until April 2015. From August 2004 until April 2009, Mr. Sisitsky served as Vice President, Legal – Corporate Finance at American Tower Corporation, a global owner and operator of wireless communication sites. Prior to joining American Tower, Mr. Sisitsky was a Junior Partner in the Corporate Department of Wilmer Cutler Pickering Hale and Dorr (WilmerHale), based in Boston, MA.
- Dale Wolf
Dale Wolf自2020年1月起担任我们的高级副总裁，全球业务，负责NuVasive的供应链，分销，制造，质量保证以及房地产和设施功能。Wolf先生此前自2018年8月起担任公司的制造Vice President。在加入公司之前，Wolf先生在通用电气（General Electric GE）任职超过15年，包括在制造，运营和供应链中担任领导职务。最近，从2014年10月至2018年6月，沃尔夫先生担任通用电气梦百合的执行工厂经理。
Dale Wolf,has served as Nuvasive, Inc. Senior Vice President, Global Operations since January 2020 and is responsible for NuVasive's supply chain, distribution, manufacturing, quality assurance and real estate and facilities functions.Mr. Wolf previously served as the Company's Vice President, Manufacturing, since August 2018. Prior to joining the Company, Mr. Wolf spent over 15 years with General Electric (GE), including leadership roles in manufacturing, operations and supply chain. Most recently, from October 2014 to June 2018, Mr. Wolf served as an executive plant manager for GE Healthcare.- Dale Wolf自2020年1月起担任我们的高级副总裁，全球业务，负责NuVasive的供应链，分销，制造，质量保证以及房地产和设施功能。Wolf先生此前自2018年8月起担任公司的制造Vice President。在加入公司之前，Wolf先生在通用电气（General Electric GE）任职超过15年，包括在制造，运营和供应链中担任领导职务。最近，从2014年10月至2018年6月，沃尔夫先生担任通用电气梦百合的执行工厂经理。
- Dale Wolf,has served as Nuvasive, Inc. Senior Vice President, Global Operations since January 2020 and is responsible for NuVasive's supply chain, distribution, manufacturing, quality assurance and real estate and facilities functions.Mr. Wolf previously served as the Company's Vice President, Manufacturing, since August 2018. Prior to joining the Company, Mr. Wolf spent over 15 years with General Electric (GE), including leadership roles in manufacturing, operations and supply chain. Most recently, from October 2014 to June 2018, Mr. Wolf served as an executive plant manager for GE Healthcare.
- Michael Farrington
Michael Farrington，自2022年9月起担任Nuvasive, Inc.人与文化高级副总裁，负责公司的人力资源、人才和总奖励，以及企业营销、品牌和传播职能。自2016年加入NuVasive以来，Farrington先生在NuVasive担任过多个领导职务，最近担任企业营销、品牌和传播高级副总裁。法灵顿先生在塑造公司的品牌和文化方面发挥了不可或缺的作用，包括设计了“猎豹之道”，在公司员工资源集团（ERG）顾问委员会任职，并领导了许多企业范围内的文化项目和计划。在加入NuVasive之前，他曾在Becton Dickinson、CareFusion和卡地纳健康等全球医疗技术公司担任多个企业、品牌和产品营销职位。
Michael Farrington,has served as Nuvasive, Inc. Senior Vice President, People and Culture, since September 2022, and is responsible for the Company's human resources, talent, and total rewards, and corporate marketing, brand and communication functions.Since joining NuVasive in 2016, Mr. Farrington has held various leadership roles at NuVasive, and most recently served as Senior Vice President, Corporate Marketing, Brand and Communications. Mr. Farrington has played an integral role in shaping the Company's brand and culture—including architecting The Cheetah Way, serving on Company Employee Resource Group (ERG) advisory boards and leading many enterprise-wide cultural projects and initiatives. Before joining NuVasive, he held a variety of corporate, brand and product marketing positions in global, medical technology companies including Becton Dickinson, CareFusion and Cardinal Health.- Michael Farrington，自2022年9月起担任Nuvasive, Inc.人与文化高级副总裁，负责公司的人力资源、人才和总奖励，以及企业营销、品牌和传播职能。自2016年加入NuVasive以来，Farrington先生在NuVasive担任过多个领导职务，最近担任企业营销、品牌和传播高级副总裁。法灵顿先生在塑造公司的品牌和文化方面发挥了不可或缺的作用，包括设计了“猎豹之道”，在公司员工资源集团（ERG）顾问委员会任职，并领导了许多企业范围内的文化项目和计划。在加入NuVasive之前，他曾在Becton Dickinson、CareFusion和卡地纳健康等全球医疗技术公司担任多个企业、品牌和产品营销职位。
- Michael Farrington,has served as Nuvasive, Inc. Senior Vice President, People and Culture, since September 2022, and is responsible for the Company's human resources, talent, and total rewards, and corporate marketing, brand and communication functions.Since joining NuVasive in 2016, Mr. Farrington has held various leadership roles at NuVasive, and most recently served as Senior Vice President, Corporate Marketing, Brand and Communications. Mr. Farrington has played an integral role in shaping the Company's brand and culture—including architecting The Cheetah Way, serving on Company Employee Resource Group (ERG) advisory boards and leading many enterprise-wide cultural projects and initiatives. Before joining NuVasive, he held a variety of corporate, brand and product marketing positions in global, medical technology companies including Becton Dickinson, CareFusion and Cardinal Health.
- Matthew K. Harbaugh
Matthew K. Harbaugh，自2020年1月起担任Nuvasive, Inc.执行副总裁兼首席财务官。在加入NuVasive之前，他曾担任Mallinckrodt plc（一家全球专业制药产品公司）的高管。从2018年5月到2019年9月，他担任Mallinckrodt的专业仿制药业务总裁，从2013年7月到2018年12月，他担任Mallinckrodt的执行副总裁兼首席财务官。此前，他曾在Covidien Pharmaceuticals（2013年7月从Covidien plc分拆为Mallinckrodt plc）担任各种财务管理职位。他于2007年加入Covidien，担任多个财务和领导职务，包括担任Covidien Pharmaceuticals的首席财务官和临时总裁。在加入Covidien之前，他是Cerberus Capital Management, l.p.（一家总部位于纽约的私募股权公司）的首席财务执行官。在此之前，他在孟山都公司工作了近十年，在那里他担任投资者关系和财务方面的各种职务。
Matthew K. Harbaugh,has served as Nuvasive, Inc. Executive Vice President and Chief Financial Officer since January 2020.Prior to joining NuVasive, Mr. Harbaugh served as an executive at Mallinckrodt plc, a global specialty pharmaceutical products company. From May 2018 to September 2019, he served as the President of Mallinckrodt's Specialty Generics business, and from July 2013 to December 2018, he served as Mallinckrodt's Executive Vice President and Chief Financial Officer. Mr. Harbaugh previously held a variety of financial management positions at Covidien Pharmaceuticals, which was spun-off from Covidien plc as Mallinckrodt plc in July 2013. Mr. Harbaugh joined Covidien in 2007 and served in several finance and leadership roles, including as Chief Financial Officer and Interim President of Covidien Pharmaceuticals. Prior to joining Covidien, Mr. Harbaugh was a Lead Finance Executive with Cerberus Capital Management, L.P., a New York-based private equity firm. Prior to that Mr. Harbaugh worked nearly ten years for Monsanto Company, where he held various roles in investor relations and finance.- Matthew K. Harbaugh，自2020年1月起担任Nuvasive, Inc.执行副总裁兼首席财务官。在加入NuVasive之前，他曾担任Mallinckrodt plc（一家全球专业制药产品公司）的高管。从2018年5月到2019年9月，他担任Mallinckrodt的专业仿制药业务总裁，从2013年7月到2018年12月，他担任Mallinckrodt的执行副总裁兼首席财务官。此前，他曾在Covidien Pharmaceuticals（2013年7月从Covidien plc分拆为Mallinckrodt plc）担任各种财务管理职位。他于2007年加入Covidien，担任多个财务和领导职务，包括担任Covidien Pharmaceuticals的首席财务官和临时总裁。在加入Covidien之前，他是Cerberus Capital Management, l.p.（一家总部位于纽约的私募股权公司）的首席财务执行官。在此之前，他在孟山都公司工作了近十年，在那里他担任投资者关系和财务方面的各种职务。
- Matthew K. Harbaugh,has served as Nuvasive, Inc. Executive Vice President and Chief Financial Officer since January 2020.Prior to joining NuVasive, Mr. Harbaugh served as an executive at Mallinckrodt plc, a global specialty pharmaceutical products company. From May 2018 to September 2019, he served as the President of Mallinckrodt's Specialty Generics business, and from July 2013 to December 2018, he served as Mallinckrodt's Executive Vice President and Chief Financial Officer. Mr. Harbaugh previously held a variety of financial management positions at Covidien Pharmaceuticals, which was spun-off from Covidien plc as Mallinckrodt plc in July 2013. Mr. Harbaugh joined Covidien in 2007 and served in several finance and leadership roles, including as Chief Financial Officer and Interim President of Covidien Pharmaceuticals. Prior to joining Covidien, Mr. Harbaugh was a Lead Finance Executive with Cerberus Capital Management, L.P., a New York-based private equity firm. Prior to that Mr. Harbaugh worked nearly ten years for Monsanto Company, where he held various roles in investor relations and finance.